Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11186MR)

This product GTTS-WQ11186MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ11186MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11132MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MDX-1103
GTTS-WQ941MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-321
GTTS-WQ9335MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ7972MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GX-17
GTTS-WQ15707MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA VIR-7831
GTTS-WQ5728MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ13105MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-03446962
GTTS-WQ6809MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DSTP-3086S
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW